Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04112810 · ClinicalTrials.gov registry record · Phase 2
Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT04112810 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 51 participants.
The verdict
NCT04112810, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is a phase 2 open-label trial designed to evaluate the efficacy of tildrakizumab in improving graft-versus-host disease (GVHD)-free relapse-free survival after myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.
Interventions
- DRUG Tildrakizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2024-06-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04112810
The ClinicalTrials.gov registry entry for NCT04112810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tildrakizumab is the first listed.
NCT04112810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04112810 about?
NCT04112810 is a clinical study titled "Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease". This is a phase 2 open-label trial designed to evaluate the efficacy of tildrakizumab in improving graft-versus-host disease (GVHD)-free relapse-free survival after myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.
What is the current status of trial NCT04112810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2020-03-01. Estimated completion is 2024-06-17.
What interventions are being tested in trial NCT04112810?
The interventions under investigation include: Tildrakizumab (DRUG).
Who is sponsoring clinical trial NCT04112810?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.